FDA Holds Up HeartWare LVAD Trial In Less Advanced Heart Failure Patients
This article was originally published in The Gray Sheet
Executive Summary
Investigators for the REVIVE-IT pilot study received a second deficiency letter from FDA May 11; researchers say they continue to work with the agency to move forward on the 100-patient, randomized trial.